Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: A new simulation model
References (53)
- et al.
Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway
Vaccine.
(2008) - et al.
Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998–2006)
Vaccine.
(2007) - et al.
Epidemiological differences among pneumococcal serotypes
Lancet Infect Dis.
(2005) - et al.
Serotypes and pathogens in pae-diatric pneumonia
Vaccine.
(2008) - et al.
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised doubleblind efficacy study
Lancet.
(2006) - et al.
Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination—a review (2002–2006)
Vaccine.
(2007) - et al.
How to compare the efficacy of conjugate vaccines to prevent acute otitis media?
Vaccine.
(2009) Serotype replacement in perspective
Vaccine.
(2009)- et al.
Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada
Vaccine.
(2003) - et al.
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: A matched case-control study
Lancet.
(2006)
Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England
J Infect.
(2007)
Costeffectiveness analysis of pneumococcal conjugate vaccination in England and Wales
Vaccine.
(2004)
Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente
Vaccine.
(2000)
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis
Lancet
(2007)
Impact of the introduction of pneu-mococcal conjugate vaccine on rates of community acquired pneumonia in children and adults
Vaccine.
(2008)
Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR
Clin Microbiol Infect.
(2008)
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine
N Engl J Med.
(2003)
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
Pediatr Infect Dis J.
(2000)
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
Pediatrics.
(1998)
Pneumococcal. Immunisation Against Infectious Disease—“The Green Book.”
Invasive pneumococcal disease in children: Geographic and temporal variations in incidence and serotype distribution
Eur J Pediatr.
(2002)
Phase 3 data indicate investigational 13-valent vaccine may broaden protection against pneumococcal disease in children younger than two (press release)
(2008)
GlaxoSmithKline's pneumococcal vaccine, receives European authorisation (press release)
(2009)
Cost-effectiveness of pneumococcal conjugate vaccine: Evidence from the first 5 years of use in the United States incorporating herd effects
Pediatr Infect Dis J.
(2006)
Pneumococcal immunization program: Cost-utility analysis for Quebec
CanJ Infect Dis.
(1999)
Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines
Pediatr Infect Dis J.
(2009)
Cited by (41)
Constrained Optimization for Pneumococcal Vaccination in Brazil
2021, Value in Health Regional IssuesPneumococcal Conjugated Vaccines Decreased Acute Otitis Media Burden: A Population-Based Study in Israel
2021, Journal of PediatricsDynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations
2020, Clinical Microbiology and InfectionCitation Excerpt :Transmission models can be deterministic, which yield the expected number of cohorts of people according to their infectious state (S, E, I, R) and the parameters, or individual-based, which are simulations that possess an inherent randomness and stochasticity that is governed by behavioural rules. While several static transmission models have been developed [15–19], these do not account for the change in indirect effects over time, and therefore are not able to capture the post-vaccination dynamics as effectively as dynamic transmission models (DTMs). As DTMs aid us in estimating the indirect effects and disease reduction caused by vaccination, they can be extended to evaluate the economic benefit of choosing one vaccine over another.
Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines
2017, Plotkin's Vaccines
Copyright © 2009 Published by Elsevier Inc.